Investors put €10m into new fast and low-cost Dx tech
This article was originally published in Clinica
Executive Summary
Biocartis, a Swiss start-up developing a novel diagnostics platform for low to highly multiplexed bioanalyte detection, has raised €10m ($14.9m) in a series A financing round. The funds were provided by a syndicate of investors, which was led by Aescap Venture and included Biovest, KBC Private Equity, Advent Venture Partners and existing Biocartis shareholder Benaruca. The proceeds will enable Lausanne-based Biocartis to develop a commercial version of its proprietary platform technology and first prototype assays. The company's focus is on bringing to market a versatile, compact diagnostics system that can be used across a wide range of settings and "drastically" reduce the time and costs of testing.